Article
Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin.
Clinical pharmacology and therapeutics - 1 Dec 2001
Mulder A B, van Lijf H J, Bon M A, van den Bergh F A, Touw D J, Neef C, Vermes I
Abstract excerpt
OBJECTIVE: Because clinical data about the therapeutic consequences of polymorphic oxidation of simvastatin by CYP2D6 have not been well reported, we sought to investigate the possible link between polymorphism of CYP2D6 and the efficacy and tolerability of simvastatin treatment in a group of 88 patients with hypercholesterolemia. METHODS: The CYP2D6 genotype was determined with use of polymerase chain reaction...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
